OR
CLICK HERE TO REGISTER AT NO COST
SAVE 20% - 50% ON
Medical Supplies
You are not eligible to purchase this product. Please contact your account manager for more information.
Additional Information
Description
Eylea 40 mg/mL (0.05 mL prefilled syringe) is an intravitreal anti-vascular endothelial growth factor (VEGF) agent used for the treatment of retinal diseases. It contains aflibercept, a recombinant fusion protein that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing abnormal blood vessel growth and leakage in the retina. This targeted inhibition reduces macular edema and neovascularization, preserving vision in patients with retinal disorders.
The primary indications for Eylea include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema secondary to retinal vein occlusion (RVO). By inhibiting pathological angiogenesis and vascular permeability, Eylea stabilizes or improves visual acuity.
Eylea is administered via intravitreal injection by a qualified healthcare professional under aseptic conditions. Proper patient monitoring is necessary to detect potential complications, including intraocular inflammation, retinal detachment, increased intraocular pressure, and endophthalmitis.
You've just added this product to thecart: